{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Fadlalla M"],"pubmed_abstract":["<h4>Purpose of review</h4>This article provides a review of the recent literature related to the FDA-approved drugs that had been repurposed as potential drug candidates against COVID-19. Moreover, we performed a quality pharmacophore study for frequently studied targets, namely, the main protease, RNA-dependent RNA polymerase, and spike protein.<h4>Recent findings</h4>Ever since the COVID-19 pandemic, the whole spectrum of scientific community is still unable to invent an absolute therapeutic agent for COVID-19. Considering such a fact, drug repurposing strategies seem a truly viable approach to develop novel therapeutic interventions.<h4>Summery</h4>Drug repurposing explores previously approved drugs of known safety and pharmacokinetics profile for possible new effects, reducing the cost, time, and predicting prospective side effects and drug interactions. COVID-19 virulent machinery appeared similar to other viruses, making antiviral agents widely repurposed in pursuit for curative candidates. Our main protease pharmacophoric study revealed multiple features and could be a probable starting point for upcoming research."],"journal":["Current pharmacology reports"],"pagination":["212-226"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8970976"],"repository":["biostudies-literature"],"pubmed_title":["Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models."],"pmcid":["PMC8970976"],"pubmed_authors":["Fadlalla M","Elshiekh AA","Yousef BA","Ali M","Ahmed M"],"additional_accession":[]},"is_claimable":false,"name":"Molecular Docking as a Potential Approach in Repurposing Drugs Against COVID-19: a Systematic Review and Novel Pharmacophore Models.","description":"<h4>Purpose of review</h4>This article provides a review of the recent literature related to the FDA-approved drugs that had been repurposed as potential drug candidates against COVID-19. Moreover, we performed a quality pharmacophore study for frequently studied targets, namely, the main protease, RNA-dependent RNA polymerase, and spike protein.<h4>Recent findings</h4>Ever since the COVID-19 pandemic, the whole spectrum of scientific community is still unable to invent an absolute therapeutic agent for COVID-19. Considering such a fact, drug repurposing strategies seem a truly viable approach to develop novel therapeutic interventions.<h4>Summery</h4>Drug repurposing explores previously approved drugs of known safety and pharmacokinetics profile for possible new effects, reducing the cost, time, and predicting prospective side effects and drug interactions. COVID-19 virulent machinery appeared similar to other viruses, making antiviral agents widely repurposed in pursuit for curative candidates. Our main protease pharmacophoric study revealed multiple features and could be a probable starting point for upcoming research.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T19:32:04.682Z","creation":"2025-02-19T02:58:06.812Z"},"accession":"S-EPMC8970976","cross_references":{"pubmed":["35381996"],"doi":["10.1007/s40495-022-00285-w"]}}